Open enrollment GLP-1 coverage depends on your exact plan, the medicine, and the reason it was prescribed. A plan can cover diabetes treatment while excluding weight management. Last year's approval doesn't settle next year's coverage.
GLP-1 medicines act on a gut-hormone signal involved in appetite and blood sugar. For someone already prescribed one, this fall's useful question is simple: will the next plan pay for the next refill?
Open enrollment GLP-1 coverage: the dates that matter
As of September 30, 2026, the day this article was written, Medicare lists October 15 through December 7 as its annual enrollment window. Changes take effect January 1. Part D is Medicare's prescription-drug benefit.
HealthCare.gov says enrollment for 2027 coverage starts November 1. December 15 is its deadline for January 1 coverage. State-run Marketplace calendars need their own check. Employer enrollment often happens in the fall, with dates set by the employer.
| Coverage route | Calendar check | Documents worth comparing |
|---|---|---|
| Medicare health and drug plans | October 15–December 7 | Annual Notice of Change, the plan's letter about next year's benefits; 2027 drug list |
| HealthCare.gov Marketplace | November 1 opening; December 15 for January 1 coverage | Exact plan's 2027 drug list and coverage criteria |
| Employer plan | Employer's deadline | Benefits guide, drug list, and weight-management exclusions |
As of September 30, 2026, the day this article was written, CMS has announced clearer plan comparisons. The September 28, 2026 release says better links to plan documents will appear starting in October. That makes the actual drug list easier to check.
Will my insurance cover Wegovy in 2027?
The answer lives in two places: the formulary, the plan's covered-drug list, and the benefit documents that define exclusions. A drug can appear on a list while a particular use remains excluded.
A useful search names Wegovy, Zepbound, and Foundayo separately. It also names the exact form: tablet, pen, or vial. Wegovy contains semaglutide; Zepbound contains tirzepatide. Another brand sharing an ingredient doesn't inherit the same coverage.
The question for the benefits team is specific: “Does this exact 2027 plan cover this product for my documented condition?” The answer needs the plan name, coverage year, product form, and written criteria.
Promise's compounded semaglutide is a separate pharmacy-prepared formulation from Wegovy, prescribed only after a licensed provider reviews the request.
Employer plan GLP-1 coverage for 2027
As of September 30, 2026, the day this article was written, the Business Group on Health's August 25 release reports a coverage pullback. Among surveyed employers, obesity GLP-1 coverage fell from 72% in 2025 to 60% in 2026. The survey covered 127 employers, so those figures describe that group. Our guide to insurance dropping GLP-1 coverage explains the broader changes.
How to read prior authorization, step therapy, and limits
A listing is the start of the check. The abbreviations beside it describe what happens before a covered prescription reaches the pharmacy.
| Plan wording | Plain meaning | Question for the plan |
|---|---|---|
| PA: prior authorization | The plan reviews medical information before agreeing to pay | Which records are required, and how long does approval last? |
| ST: step therapy | The plan requires another treatment first unless it grants an exception | Do previous treatments count? |
| QL: quantity limit | The plan caps how much medicine it covers within a set period | Does the limit fit the prescribed product and refill schedule? |
| Tier | The plan's payment category for that drug | What is my share at a participating pharmacy? |
Medicare explains these coverage rules and exception requests. Commercial plans have their own documents and review processes.
A 2025 study in JAMA Network Open examined Medicare Part D coverage for Ozempic, Mounjaro, and Rybelsus. Its records ran through the third quarter of 2024. Among covering plans, prior authorization applied to more than 8 in 10 for each medicine. Those historical figures describe those brands, rather than 2027 Wegovy or Zepbound benefits.
For an existing Zepbound prescription, another question is whether the new plan accepts the current approval or requires a fresh review. Starting-treatment and renewal criteria can differ.
Medicare's Bridge is a separate coverage check
The Medicare GLP-1 Bridge is a temporary program with its own eligibility rules, separate from Part D's coverage and payment process. A plan doesn't have to opt in.
As of September 30, 2026, the day this article was written, CMS's Bridge page, last modified July 13, 2026, confirms that separate route. Our Medicare GLP-1 coverage guide explains eligibility, product forms, and the program's patient payments.
For open enrollment, the distinction is practical: a missing weight-management benefit in a Part D formulary doesn't answer the Bridge eligibility question. The rest of the plan's medicines, pharmacies, and benefits still matter.
The refill budget matters as much as the premium
The premium is the regular payment for insurance. The deductible is spending required before certain benefits pay. A copay is a fixed patient payment; coinsurance is a percentage. A full-year comparison includes all four, plus visits and supplies.
As of September 30, 2026, the day this article was written, a new JAMA Health Forum study adds evidence about affordability. It was published August 28, 2026, and examined 8,914 commercially insured adults starting semaglutide in 2021–2022.
After accounting for patient differences, inconsistent use was about 9 percentage points more common in the highest-cost group. That's roughly 9 more people in every 100, compared with the lowest-cost group. Inconsistent use meant prescription fills covered less than 80% of the follow-up year. The study found an association; fill records cannot confirm which doses people took.
LillyDirect, NovoCare, and TrumpRx connect patients with manufacturer cash offers. Our TrumpRx GLP-1 prices guide compares the routes and refill terms. NovoCare's current terms say its cash purchases don't count toward insurance deductibles or out-of-pocket requirements.
A compounded prescription has its own payment question. The U.S. Food and Drug Administration (FDA) explains that compounded medicines are prepared for individual needs. Promise's semaglutide and tirzepatide are compounded medications, different from an FDA-approved product: the formulations offered here are not FDA-approved.
A licensed provider may still prescribe a compounded formulation within applicable rules; that decision is between the patient and the doctor. At Promise, semaglutide and tirzepatide each have their own intake questionnaire.
Before the first refill under the new plan
The useful comparison fits on one page: enrollment deadline, exact medicine and form, covered condition, approval requirements, pharmacy, patient share, and renewal date. A saved copy of the plan's answer gives the prescriber and pharmacy something concrete to work with.
Coverage delays also belong in the clinical conversation. As of September 30, 2026, the day this article was written, Wegovy’s current label carries “Revised: 6/2026”. For injections, it directs restarting gradual dose increases at a lower dose after two or more consecutive missed doses. Its stated purpose is reducing digestive side effects. The prescriber sets the actual dosing plan.
At Promise, a licensed U.S. provider reviews every request and may prescribe or decline; not everyone qualifies.
